TT-232

CAT: 0804-HY-105172-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-105172-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[1][2][4].
CAS Number
[147159-51-1]
Product Name Alternative
CAP-232; TLN-232
UNSPSC
12352209
Target
Somatostatin Receptor
Type
Peptides
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tt-232.html
Purity
98.72
Solubility
H2O : < 0.1 mg/mL (ultrasonic)
Smiles
O=C(N[C@H](C(N[C@@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CCCCN)[C@H](NC([C@@H](NC([C@H](CSSC1)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC(C=C3)=CC=C3O)=O)CC4=CNC5=CC=CC=C45
Molecular Formula
C45H58N10O9S2
Molecular Weight
947.13
References & Citations
[1]Szende B, et al. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs. 2003 Sep;14 (8) :585-8. |[2]Kéri G, et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A. 1996 Oct 29;93 (22) :12513-8. |[3]Tejeda M, et al. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Res. 2005 Jan-Feb;25 (1A) :325-30. |[4]Pintér E, et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366 (2) :142-50.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Scientific Category
Peptides
Clinical Information
Phase 2
Isoform
SSTR1; SSTR4

Popular Products